1. Home
  2. ACXP vs SPHL Comparison

ACXP vs SPHL Comparison

Compare ACXP & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.39

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

HOLD

Current Price

$2.52

Market Cap

5.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACXP
SPHL
Founded
2017
2002
Country
United States
Singapore
Employees
N/A
73
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ACXP
SPHL
Price
$1.39
$2.52
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$95.50
N/A
AVG Volume (30 Days)
86.2K
191.1K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.35
52 Week High
$8.34
$25.11

Technical Indicators

Market Signals
Indicator
ACXP
SPHL
Relative Strength Index (RSI) 38.23 43.39
Support Level $1.36 $2.48
Resistance Level $1.75 $3.10
Average True Range (ATR) 0.10 0.17
MACD -0.01 -0.02
Stochastic Oscillator 1.25 2.15

Price Performance

Historical Comparison
ACXP
SPHL

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: